Article information
Resumen
Presentamos un caso clínico que describe un paciente joven con aplastamientos vertebrales en varios niveles secundarios a fragilidad osteoporótica. Describimos las características clínicas de la osteoporosis en el varón, destacando la importancia de una enfermedad habitualmente infradiagnosticada y considerada tradicionalmente como propia de la mujer postmenopáusica.
Palabras clave:
Osteoporosis
varón
aplastamiento vertebral
Abstract
We report the case of multiple osteoporotic vertebral fractures in a young man and describe the clinical characteristics of osteoporosis in the male. Osteoporosis is generally considered a disease of postmenopausal women, as a result, osteoporosis in men is an underdiagnosed and undertreated problem.
Key words:
Osteoporosis
men
vertebral fractures
Laburpena
Hainbat orno-aplastamendu dituen gizon gazte baten kaso klinikoa aurkezten dugu. Aplastamendu horiek hainbat mailatan aurkezten ditu eta osteoporosiak eragindako hauskortasunaren ondorio dira. Kontutan harturik osteoporosiari daukan garrantzia kentzen zaiola eta klasikoki emakumezkoen gaitz konsideratu dela, gizonezkoengan dituen ezaugarriak deskribatuko ditugu.
Giltza hitzak:
Osteoporosi
gizon
orno-aplastamendu
Full text is only aviable in PDF
Bibliografía
[1.]
Schuit S.C., Van der Klift, Weel A.E., De Laet C.E., Burger H., Seeman E., Hofman A., Uitterlinden A.G., Van Leeuwen J.P., Pols H.A..
Fracture incidence and association with bone mineral density in ederly men and women: the Rotterdam Study.
Bone, 34 (2004), pp. 195-202
[2.]
Cooper C..
Epidemiology of osteoporosis.
Osteoporosis Int., 9 (1999), pp. S2-S8
[3.]
Díaz Curiel M., Espinoza Pineda J..
Osteoporosis en el varön en España.
REEMO, 12 (2003), pp. 1-3
[4.]
Center J.R., Nguyen T.V., Schneider D., Sambrook P.N., Eisman J.A..
Mortality alter all major types of osteoporotic fracture in men and women: an observational study.
Lancet, 353 (1999), pp. 878-882
[5.]
González Macías J..
Osteoporosis del varön: epidemiología y patogenia.
Manual práctico de osteoporosis y enfermedades del metabolismo mineral, pp. 249-254
[6.]
Díaz Curiel M., Carrasco de la Peña J.L., Honorato Pérez J., Pérez Cano R., Rapado A., Ruiz Martínez I..
Study of bone mineral density in lumbar spine and femoral neck in spanish population.
Osteoporosis Int., 7 (1997), pp. 59-64
[7.]
Wishart J.M., Need A.G., Horowitz M., Morris A., Nordin B.E.C..
Effect of age on bone density and bone turnover in men.
Clin Endocrinology, 42 (1995), pp. 141-146
[8.]
Peris P..
Osteoporosis en el varön. ¿Cömo diagnosticarla y tratarla.
Rev Esp Reumatol., 28 (2001), pp. 135-142
[9.]
Martínez Díaz Guerra G., Díaz Curiel M., Hawkins Carranza F..
Factores predictivos de osteoporosis densitométrica en varones sanos de edad avanzada.
REEMO, 13 (2004), pp. 5-12
[10.]
Bilezikian J.P., Morishima A., Bell J., Grumbach M.M..
Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency.
N Engl J Med., 339 (1998), pp. 599-603
[11.]
Peris P., Guañabens N., Pares A., Pons F., Del Rio L., Monegal A., Surís X., Caballería J., Rodés J., Muñoz Gömez J..
Vertebral fractures and osteopenia in chronic alcoholic patients.
Calcif Tissue Int., 57 (1995), pp. 111-114
[12.]
Poor G., Atkinson E.J., Otallon W.M., Melton L.J. 3rd.
Predictors of hip fracture in ederly men.
J Bone Miner Res., 10 (1995), pp. 1900-1907
[13.]
Lane N.E..
An update on glucocorticoid-induced osteoporosis.
Rheum Dis Clin North Am., 27 (2001), pp. 235-253
[14.]
MacAdams M.R., White R.H., Chipps B.E..
Reduction of serum testosterone levels during chronic glucocorticoid therapy.
Ann Intern Med., 104 (1986), pp. 648-651
[15.]
van Staa T.P., Leufkens H.G., Cooper C..
The epidemiology of corticoisteroid-induced osteoporosis: a meta-analysis.
Osteoporos Int., 13 (2002), pp. 777-787
[16.]
de Vries F., Pouwels S., Lammers J.W., Leufkens H.G., Bracke M., Cooper C., van Staa T.P..
Use of inhaled and oral glucocorticoids, severity of inflamatory disease and risk of hip/femur fracture: a population-based case-control study.
J Intern Med., 261 (2007), pp. 170-177
[17.]
Herrera Rodriguez A., Grupo de expertos en osteoporosis de la SECOT.
Recomendaciones de manejo clínico del paciente mayor de 50 años con fractura osteoporötica.
REEMO, 12 (2003), pp. 125-128
[18.]
Moro álvarez M.J., Díaz Curiel M..
Protocolo de intervenciön en la osteoporosis del varön.
Medicine, 6 (2006), pp. 49-52
[19.]
Orwoll E., Ettinger M., Weiss S., Miller P., Kendler D., Graham J., et al.
Alendronate for the treatment of osteoporosis in men.
N Engl J Med., 343 (2000), pp. 604-610
[20.]
Ringe J.D., Dorst A., Faber H., Ibach K..
Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two arm study.
Rheumatology Int., 24 (2004), pp. 110-113
[21.]
Ringe J.D., Faber H., Farahmand P., Dorst A..
Efficacy of risedronate in men with primary and secondary osteoporosis.
Results of a 1-year study. Rheumatol Int., 26 (2006), pp. 427-431
[22.]
Boonen S., Delmas P.D., Wenderoth D., Stoner K.J., Eusebio R., Orwoll E.S..
Risedronate shown to be safe and effective in men with osteoporosis in a 2-year, double-blind, randomized, placebo-controlled, multicenter study.
Osteoporos Int., 17 (2006), pp. S230-1
[23.]
Kauffman J.M., Scheele W.H., Orwoll E., Clancy A.D., Adami S., Syversen U., et al.
Recombinant human parathyroid hormone (1-34) therapy increases bone mineral density and may decrease the risk of fractures in men with low bone density.
Osteoporos Int., 12 (2001), pp. S13
[24.]
Orwoll E., Scheele W.H., Paul S., Adami S., Syversen U., Diez-Perez A., et al.
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men osteoporosis.
J Bone Miner Res., 18 (2003), pp. 9-17
Copyright © 2008. Academia de Ciencias Médicas de Bilbao